Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma

Cancer

Volumn 82, Issue 2, 1998, Pages 301-308

  Glisson, Bonnie ^a   Lee, Jin S ^a   Palmer, Judy ^a   Fossella, Frank ^a   Shin, Dong M ^a   Murphy, William K ^a   Perez Soler, Roman ^a   Hong, Waun Ki ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chemotherapy; Cisplatin; Ifosfamide; Oral etoposide; Small cell lung carcinoma

Indexed keywords

CISPLATIN; ETOPOSIDE; IFOSFAMIDE; MESNA;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; FEMALE; HEARING IMPAIRMENT; HEMATURIA; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; METASTASIS; MOTOR DYSFUNCTION; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; GRANULOCYTES; HUMANS; IFOSFAMIDE; LEUKOCYTE COUNT; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; NEUTROPENIA; REMISSION INDUCTION; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

EID: 0031965077     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980115)82:2<309::AID-CNCR9>3.0.CO;2-L     Document Type: Article

References (25)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-28.
2. Johnson BE, Grayson J, Makuch RW, Linnoila RI, Anderson MJ, Cohen MH, et al. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with of without irradiation. J Clin Oncol 1990;8:396-401.
3. Crown JPA, Chahinian AP, Jaffrey IS, Glidewell OJ, Kaneko M, Holland JF. Predictors of 5-year survival and curability in small cell lung cancer. Cancer 1992;66:382-6.
4. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Cline Once 1992;10: 282-91.
5. Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994;12:2022-34.
6. Johnson DH, Hainsworth JD, Hande KR, Greco FA. Current status of etoposide in the management of small cell lung cancer. Cancer 1991;67:231-44.
7. Clark PI, Joel SP, Thompson PI, Slevin ML. Prolonged administratin of single-agent oral etoposide in patients with untreated small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1990;9:226.
8. Johnson DH, Greco AF, Strupp J, Hande KR, Hainsworth JD. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 1990;8:1613-7.
9. Einhorn LH, Pennington K, McClean J. Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Semin Oncol 1990;7:32-5.
10. Warenius HM, Hurman DC, Cottier B. High-dose ifosfamide in small cell lung cancer [abstract]. Br J Cancer 1986;54:216.
11. Einhorn LH. Ifosfamide in small cell lung cancer. Semin Oncol 1989;16:19-21.
12. Thatcher N, Lind M, Stout R, Payne C, Carroll KB, Campbell C, et al. Carboplatin, ifosfamide, and etoposide with mid-course vincristine and thoracic radiotherapy for limited stage small cell carcinoma of the bronchus. Br J Cancer 1989;60:98-101.
13. Smith IE, Perren T, Ashley SA, Woodiwiss J, Forgeson GV, Yarnold JR, et al. Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small cell lung carcinoma. J Clin Oncol 1987;6:179.
14. Loehrer PJ, Rynard S, Ansari R, Songer J, Pennington K, Einhorn L. Etoposide, ifosfamide and cisplatin in extensive small cell lung cancer. Cancer 1992;69:669-73.
15. Shirinian MS, Lee JS, Dhingra H, Greenberg J, Hong WK. Phase II study of cisplatin, ifosfamide with mesna, and etoposide chemotherapy for advanced non-small cell lung cancer. Final report. Semin Oncol 1991;19(Suppl 12):58-63.
16. Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer 1981;47:207-14.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
18. Lee JS, Murphy WK, Glisson BS, Dhingra HM, Holoye PY, Hong WK. Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol 1989;7:916-22.
19. Dombernowsky P, Nissen NI. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC 141540) in L1210 leukemia. Acta Pathol Microbiol Scand 1973;81:715-24.
20. Slevin ML, Clark PI, Joel SP, Osborne RJ, Talbot DI, Johnson PWM, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989;7:1333-40.
21. Boni C, Cocconi G, Bisagni G, Ceci G, Peracchia G. Cisplatin and etoposide as a single regimen for small cell lung cancer: a phase II trial. Cancer 1989;63:638-42.
22. Rowland KM, Loprinzi CL, Shaw EG, Maksymiuk AW, Kuross SA, Jung SH, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 1996;14:135-41.
23. Loehrer PJ, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995;13:2594-9.
24. Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD, et al. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1995;13: 1615-22.
25. Miller AA, Herndon JE II, Hollis DR, Ellerton J, Langleben A, Richards F, et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1995;13:1871-9.